MINNEAPOLIS, July 10, 2014 /PRNewswire/ -- Uroplasty,
Inc. (NASDAQ: UPI), a medical device company that develops,
manufactures and markets innovative proprietary products for the
treatment of voiding dysfunctions, will release financial results
for the first quarter ended June 30,
2014 after the market close on Thursday, July 24, 2014.
The Company will host a conference call and webcast to discuss
these results on Thursday, July 24,
2014 at 4:30 p.m. Eastern Time
(3:30 p.m. Central Time).
Rob Kill, President and Chief
Executive Officer, and Brett
Reynolds, Chief Financial Officer, will host the event.
Individuals wishing to participate in the conference call should
dial 888-505-4375. No passcode is necessary. To access a live
webcast of the call, go to Uroplasty's website at www.uroplasty.com
and click on the Events Section of the Investor Relations page.
An audio replay will be available for 30 days following the call
at 888-203-1112 with the passcode 7876225. An archived webcast will
also be available at investor.uroplasty.com.
About Uroplasty, Inc.
Uroplasty, Inc., headquartered in Minnetonka, Minnesota, with wholly-owned
subsidiaries in The Netherlands
and the United Kingdom, is a
global medical device company that develops, manufactures and
markets innovative proprietary products for the treatment of
voiding dysfunctions. Our focus is the continued commercialization
of our Urgent® PC Neuromodulation System, the only commercially
available, FDA-cleared system that delivers percutaneous tibial
nerve stimulation (PTNS) for the office-based treatment of
overactive bladder (OAB). OAB is a chronic condition that affects
approximately 42 million U.S. adults. The symptoms include
urinary urgency, frequency and urge incontinence. We also
offer Macroplastique®, an injectable urethral bulking agent for the
treatment of adult female stress urinary incontinence primarily due
to intrinsic sphincter deficiency. For more information on the
company and its products, please visit Uroplasty, Inc. at
www.uroplasty.com.
For Further Information:
Uroplasty, Inc.
Brett Reynolds, SVP and
CFO
952.426.6152
EVC Group
Doug Sherk (Investors)/Janine McCargo (Business Media)
415.652.9100/646.688.0245
SOURCE Uroplasty, Inc.